Testosterone Cypionate Dosage Guide for TRT

Testosterone cypionate is the most widely prescribed injectable testosterone ester in the United States, and for good reason — its relatively long half-life makes it practical, its bioavailability is consistent, and decades of clinical data support its use in testosterone replacement therapy (TRT). But dosing it correctly requires more than picking a number. The right dose is the one that brings your levels into the physiological range, resolves your symptoms, and does so without producing unnecessary side effects.

What Is Testosterone Cypionate and How Does It Work?

Testosterone cypionate is a synthetic ester of testosterone attached to a cypionate ester chain. After intramuscular (or subcutaneous) injection, the ester is cleaved by esterases in the bloodstream, releasing free testosterone. The cypionate ester gives it an effective half-life of approximately 8 days, meaning a single injection sustains elevated testosterone levels for roughly 10–14 days — though most clinical protocols use weekly or twice-weekly injections to minimize peaks and troughs.

Testosterone exerts its effects by binding to androgen receptors in target tissues throughout the body: muscle, bone, brain, liver, prostate, skin, and more. In men with hypogonadism — defined clinically as total testosterone below approximately 300 ng/dL accompanied by symptoms — exogenous testosterone replaces what the testes are no longer producing in adequate amounts.

Standard TRT Dosage Ranges

The Endocrine Society's 2018 Clinical Practice Guidelines on testosterone therapy recommend targeting mid-normal physiological testosterone levels — generally a total testosterone of 400–700 ng/dL on a trough measurement (drawn just before the next injection). Most providers translate this into a starting dose and adjust based on labs and symptom response.

Typical Starting Doses

Standard clinical starting doses for testosterone cypionate in TRT are typically in the range of:

• 100 mg weekly — the most common starting point for men with moderate hypogonadism; conservative and easy to titrate upward
• 150 mg weekly — used when baseline testosterone is very low (<150 ng/dL) or symptoms are significant
• 200 mg every 2 weeks — an older protocol still occasionally prescribed; less ideal due to large peak-to-trough fluctuations

Many TRT-specialized providers now favor splitting the weekly dose into twice-weekly injections (e.g., 50 mg every 3.5 days) to produce steadier serum testosterone levels and reduce estradiol spikes, which can improve symptom control and tolerability.

Injection Routes: IM vs. Subcutaneous

Traditionally, testosterone cypionate was administered as a deep intramuscular (IM) injection into the gluteus or vastus lateralis. Subcutaneous (subQ) injection into abdominal or thigh fat has become increasingly common in TRT, with studies showing comparable testosterone absorption and lower injection-site discomfort (Spratt et al., 2006). SubQ may slightly slow the release, producing somewhat lower but more stable peak levels — which some patients find reduces estrogen-related side effects.

Titration: How Dosage Is Adjusted Over Time

TRT is not a set-it-and-forget-it therapy. The Endocrine Society recommends checking testosterone levels 3 months after initiating therapy or changing the dose, then annually once stable. Labs typically include total testosterone (trough level), hematocrit, PSA (in men over 40), and often estradiol.

Titration Principles

• If trough testosterone is below 400 ng/dL and symptoms persist: Increase dose by 10–20 mg weekly or shorten injection interval.
• If trough testosterone is above 700–800 ng/dL: Consider reducing dose, particularly if hematocrit is rising or estradiol symptoms are present.
• If symptoms have resolved and levels are in range: Maintain current dose; recheck labs every 6–12 months.

Symptom response is weighed alongside lab values. Some patients feel optimal at 450 ng/dL; others need 650 ng/dL. The goal is not a specific number but rather resolution of hypogonadal symptoms — fatigue, low libido, depressed mood, reduced muscle mass — without adverse effects.

Hematocrit Monitoring: A Key Safety Parameter

One of the most clinically significant effects of testosterone therapy is stimulation of erythropoiesis — the production of red blood cells. This is mediated partly through increased erythropoietin (EPO) production. In most men, this produces a modest, beneficial increase in hematocrit. However, in some patients, hematocrit can rise to levels that increase blood viscosity and theoretically cardiovascular risk.

Hematocrit Thresholds

The Endocrine Society recommends withholding testosterone therapy if hematocrit exceeds 54% and reassessing after 3–6 months. Most clinicians become attentive at hematocrit above 50–52% and may:

• Reduce the testosterone dose
• Switch from IM to subcutaneous injection, which may produce slightly lower peak levels
• Switch to a shorter-ester formulation with different pharmacokinetics
• Advise therapeutic phlebotomy in cases of significant polycythemia
• Ensure adequate hydration, as dehydration can artifactually elevate hematocrit readings

The TRAVERSE trial (Lincoff et al., 2023, NEJM), a randomized cardiovascular outcomes trial of testosterone therapy in men with hypogonadism and elevated cardiovascular risk, found no increased risk of major adverse cardiac events with TRT — but did note increased rates of pulmonary embolism and atrial fibrillation, underscoring the importance of hematocrit monitoring and individualized risk assessment.

Estradiol and Anastrozole Management

Testosterone is aromatized — converted — to estradiol (E2) by the aromatase enzyme, primarily in adipose tissue. When testosterone levels rise with TRT, estradiol typically rises as well. A moderate increase in estradiol is normal and even beneficial: estradiol plays important roles in bone density, cardiovascular health, mood, and sexual function in men.

Signs of Elevated Estradiol

However, estradiol that rises too high relative to testosterone can produce symptoms including:

• Gynecomastia (breast tissue growth or tenderness)
• Water retention and bloating
• Mood changes, irritability, or emotional lability
• Reduced libido despite adequate testosterone levels

When Anastrozole May Be Considered

Anastrozole is an aromatase inhibitor (AI) sometimes prescribed alongside TRT to manage elevated estradiol. However, its use is not routine — it is typically reserved for patients with confirmed elevated estradiol (generally above 40–50 pg/mL on a sensitive assay) who also have symptoms attributable to high estrogen. Blanket AI prescribing without confirmed lab elevation is not recommended, as over-suppression of estradiol can cause bone loss, joint pain, negative lipid changes, and sexual dysfunction (Finkelstein et al., 2013, NEJM).

When used, anastrozole is typically dosed at 0.25–0.5 mg twice weekly and titrated based on follow-up estradiol labs. The goal is not to eliminate estradiol but to keep it in the mid-normal male reference range (roughly 20–40 pg/mL on a sensitive assay).

Putting It All Together: A Typical Protocol

A representative starting TRT protocol for a 38-year-old male with total testosterone of 225 ng/dL and symptomatic hypogonadism might look like this:

• Testosterone cypionate: 100 mg/week administered as 50 mg subcutaneous injection twice weekly (every 3.5 days)
• Baseline labs: Total testosterone (trough), free testosterone, estradiol (sensitive), hematocrit/CBC, PSA, comprehensive metabolic panel
• 6-week check-in: Symptom assessment, any side effect evaluation
• 3-month labs: Repeat full panel; adjust dose if trough testosterone is outside 400–700 ng/dL target or if hematocrit is elevated
• Ongoing: Labs every 6–12 months once stable; annual PSA for men over 40

Every protocol should be individualized. Body composition (adipose tissue percentage affects aromatization), age, concurrent health conditions, and individual response all factor into the optimal dose and monitoring schedule. There is no universal "correct" dose — there is only the dose that is correct for you, validated by your labs and your symptom response.